These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 35793409

  • 1. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
    van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, Fajgenbaum DC.
    Blood Adv; 2022 Aug 23; 6(16):4773-4781. PubMed ID: 35793409
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C.
    Lancet Oncol; 2014 Aug 23; 15(9):966-74. PubMed ID: 25042199
    [Abstract] [Full Text] [Related]

  • 4. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.
    Br J Haematol; 2019 Jan 23; 184(2):232-241. PubMed ID: 30203839
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.
    Oncotarget; 2015 Oct 06; 6(30):30408-19. PubMed ID: 26327301
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H, Isnard S, Maedler-Kron C, Routy JP.
    Eur J Case Rep Intern Med; 2023 Oct 06; 10(12):004098. PubMed ID: 38077710
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
    Lyseng-Williamson KA.
    BioDrugs; 2015 Dec 06; 29(6):399-406. PubMed ID: 26394632
    [Abstract] [Full Text] [Related]

  • 13. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
    Fajgenbaum DC, Kurzrock R.
    Immunotherapy; 2016 Dec 06; 8(1):17-26. PubMed ID: 26634298
    [Abstract] [Full Text] [Related]

  • 14. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
    Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, Zhou DB, Zhong DR, Fajgenbaum DC, Li J.
    Blood; 2019 Apr 18; 133(16):1720-1728. PubMed ID: 30760451
    [Abstract] [Full Text] [Related]

  • 15. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
    Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC.
    Blood Adv; 2023 Nov 14; 7(21):6652-6664. PubMed ID: 37656441
    [Abstract] [Full Text] [Related]

  • 16. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR, Nikanjam M, Kato S, Goodman AM, Kurzrock R.
    Cureus; 2020 Jul 02; 12(7):e8967. PubMed ID: 32766009
    [Abstract] [Full Text] [Related]

  • 17. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
    Pierson SK, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, Rubenstein A, Oromendia AB, Beineke P, Fosså A, van Rhee F, Fajgenbaum DC.
    Nat Commun; 2022 Nov 24; 13(1):7236. PubMed ID: 36433996
    [Abstract] [Full Text] [Related]

  • 18. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M, Robinson D, Trundell D, Ishak J, Jen MH, Brazier J.
    Curr Med Res Opin; 2016 Jul 24; 32(7):1193-200. PubMed ID: 26972925
    [Abstract] [Full Text] [Related]

  • 19. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3659-70. PubMed ID: 23659971
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.